Form 4: Zevra Therapeutics Director Corey Michael Watton Reports Transaction
SEC Form 4 Filing
Director Corey Michael Watton reports the acquisition and disposal of Zevra Therapeutics common stock on March 28, 2025.
Summary
- On March 28, 2025, Corey Michael Watton, a director of Zevra Therapeutics, engaged in a transaction involving the company's common stock.
- Watton acquired 300 shares of common stock at a price of $7.8384 per share.
- Following the reported transaction, Watton beneficially owns 1,800 shares of Zevra Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing a transaction by a company director, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure related to insider trading activity, which is a normal part of corporate governance and regulatory compliance.
Stakeholder Impact
- The transaction may have a minor impact on shareholder sentiment, but is unlikely to be material.
Key Dates
| Date | Description |
|---|---|
| 03/28/2025 | Date of stock transaction (acquisition and disposal) |
| 03/31/2025 | Date of signature on the report |
Keywords
Form 4, Beneficial Ownership, Director, ZVRA, Zevra Therapeutics, Watton, Corey Michael Watton, Stock Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.